atorvastatin has been researched along with Acute Disease in 75 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 52 (69.33) | 29.6817 |
| 2010's | 19 (25.33) | 24.3611 |
| 2020's | 4 (5.33) | 2.80 |
| Authors | Studies |
|---|---|
| García Pajares, F; Maroto-Martín, C; Molina Terrón, PM | 1 |
| Liu, ZL; Zeng, HT; Zhang, ZX; Zhao, M; Zhong, SM | 1 |
| Chen, X; Ding, S; Wu, S; Xu, S | 1 |
| Gao, YL; Guo, JJ; Wang, M; Wang, ZY; Yu, XF | 1 |
| Bartosic, A; Kerlin, BA; Lin, E; Riedl, K; Waller, AP; Wang, TF; Wei, L | 1 |
| Andersen, LW; Chase, M; Cocchi, MN; Donnino, MW; Holmberg, MJ; Liu, X | 1 |
| Hu, MJ; Huang, PS; Jin, C; Li, Q; Liu, JD; Qian, L; Tian, XQ; Xiong, YY; Xu, J; Xu, JY; Yang, YJ | 1 |
| Chakrabarti, A; Dhamija, P; Hota, D; Kochhar, R; Sachdev, A | 1 |
| Qu, Y; Wei, L; Zhang, H | 1 |
| Andritsos, L; Benson, DM; Bingman, A; Blum, W; Bradbury, H; Chen, X; Coombes, K; Cortright, K; Daneault, B; Devine, SM; Efebera, YA; Elder, P; Garman, S; Garzon, R; Geyer, S; Hofmeister, CC; Hofstetter, J; Jaglowski, S; Kitzler, R; Klisovic, R; Lozanski, G; O'Donnell, L; Penza, S; Ranganathan, P; Scrape, SR; Vasu, S; Yu, J; Yu, X; Zhang, J | 1 |
| Hikichi, Y; Inoue, T; Inoue, Y; Kawasaki, T; Kodama, K; Komatsu, A; Komoda, H; Mine, D; Natsuaki, M; Node, K; Oyama, J; Sakuma, M; Shibata, Y; Shimomura, M; Takeuchi, M; Toyoda, S; Yamagishi, S; Yamamoto, Y | 1 |
| Lai, SW; Liao, KF; Lin, CL | 1 |
| Arnao, V; Corpora, F; Della Corte, V; Di Bona, D; Di Raimondo, D; Iacopino, DG; Maida, C; Maugeri, R; Pecoraro, R; Pinto, A; Simonetta, I; Tuttolomondo, A | 1 |
| Császár, A | 1 |
| El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Frye, RF; Johnson, MH; Kozak, A | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Cui, L; Du, W; Li, M; Liu, L; Wang, L; Yang, R; Zhang, X | 1 |
| Chou, SY; Gulmi, FA; Kamdar, C; Kim, H; Mooppan, UM | 1 |
| Abdel-Aziz, NA; Abo-Elmatty, DM; Ghattas, MH; Tawfik, MK | 1 |
| Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; L'Esperance, V; Turzyniecka, M; Walter, L | 1 |
| Aktunc, E; Arasli, M; Barut, F; Gun, BD; Kayhan, B | 1 |
| Czaikoski, PG; Dias-Junior, CA; Neto-Neves, EM; Pereira, RP; Spiller, F; Tanus-Santos, JE; Uzuelli, JA | 1 |
| Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Mizuno, K; Shinada, T; Shirakabe, A; Tomita, K; Tsurumi, M; Yokoyama, S | 1 |
| Fenech, ME; Mackay, JW; Myint, KS | 1 |
| Arnaboldi, L; Baetta, R; Bellosta, S; Bonomo, A; Corsini, A; Ferri, N; Granata, A; Miglietta, D; Oliva, F; Ongini, E | 1 |
| Lewin, JJ; Nappi, JM; Taylor, MH | 1 |
| Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A | 1 |
| Anthopoulou, A; Elisaf, M; Miltiadous, G | 1 |
| Nissen, SE | 1 |
| Böhm, M; Fries, R | 1 |
| Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA | 1 |
| Ganz, P; Kinlay, S; Leslie, SJ; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Arikian, S; Ganz, P; Schwartz, GG; Waters, D | 1 |
| Isomustajärvi, M; Laakso, J; Laaksonen, R; Lakka, TA; Lehtimäki, T; Päivä, H; Ruokonen, I; Salonen, JT; Valkonen, VP | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD | 1 |
| Li, J; Xu, Z; Ye, H; Zhao, S; Zhou, H | 1 |
| Daida, H; Miyauchi, K; Shimada, K | 1 |
| Daida, H; Kurata, T; Miyauchi, K; Okazaki, S; Sato, H; Shimada, K; Yokoyama, T | 1 |
| Lange, AP; Szucs, TD | 1 |
| McGowan, MP | 1 |
| Cannon, CP; Ray, KK | 1 |
| Dolan, JG; Nautiyal, A; Singh, S | 1 |
| Casciano, R; Gómez-Gerique, JA; Rejas, J; Stern, L | 1 |
| Schwartz, GG | 1 |
| Badaracco, R; Brizuela, M; Cialzeta, JR; Doval, H; Farías, EF; Franciosi, V; Macin, SM; Medina, F; Perna, ER; Tajer, C | 1 |
| de Graaf, J; Stalenhoef, AF; van Tits, LJ | 1 |
| Boyacioglu, S; Gur, G; Kanbay, M; Sekuk, H; Yilmaz, U | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Tselepis, AD | 1 |
| Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM | 1 |
| Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A | 1 |
| Baz, A; Clofent, J; de Castro, ML; de Luaces, C; Hermo, JA; Pérez, R | 1 |
| Qi, SS; Shen, XQ; Zeng, GF; Zhou, HN; Zhou, SH; Zhou, T | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Alves-Filho, JC; Cunha, FQ; Figueiredo-Lopes, L; Gerlach, RF; Semprini, MC; Souza-Costa, DC; Tanus-Santos, JE | 1 |
| Alhan, CC; Avkaroğullari, M; Cayli, M; Demir, M; Demirtaş, M; Dönmez, Y; Inal, T; Kanadaşi, M; Koç, M; San, M; Usal, A | 1 |
| Colonna, G; Di Sciascio, G; Fischetti, D; Miglionico, M; Montinaro, A; Pasceri, V; Patti, G; Sardella, G | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A | 1 |
| Blanco, M; Castellanos, M; Castillo, J; Dávalos, A; García-Gil, M; Leira, R; Lizasoain, I; Moro, MA; Nombela, F; Rodriguez-Yáñez, M; Serena, J; Vivancos, J | 1 |
| Abdellah, AT; Clark, AL; Cleland, JG; Coletta, AP; Khaleva, O | 1 |
| Ebdrup, L; Granfeldt, A; Hokland, M; Krog, J; Larsen, PØ; Tønnesen, E; Vestergaard, C | 1 |
| Blauw, GJ; de Man, FH; Jukema, JW; Smelt, AH; van der Laarse, A; Weverling-Rijnsburger, AW | 1 |
| Belaïche, G; Ley, G; Slama, JL | 1 |
| El Menjawi, I; Fladerer, P; Krause, R; Pohanka, E; Wenisch, C | 1 |
| Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z | 1 |
| Mikhaildis, DP; Reynolds, TR; Wierzbicki, AS | 1 |
| Chaitman, BR; Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Schwartz, GG; Waters, D; Zeiher, A | 1 |
| Barsotti, A; Brunelli, C; Ghigliotti, G; Leslie, S; Olivotti, L; Rossettin, P; Spallarossa, P | 1 |
| Mandó, OG; Ridruejo, E | 1 |
5 review(s) available for atorvastatin and Acute Disease
| Article | Year |
|---|---|
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke | 2008 |
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome | 2006 |
32 trial(s) available for atorvastatin and Acute Disease
| Article | Year |
|---|---|
A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism.
Topics: Acute Disease; Adult; Aged; Atorvastatin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Venous Thromboembolism; Young Adult | 2021 |
Coenzyme Q10 in acute influenza.
Topics: Acute Disease; Adult; Atorvastatin; Biomarkers; Double-Blind Method; Female; Humans; Inflammation; Influenza, Human; Male; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Tertiary Care Centers; Ubiquinone; Young Adult | 2019 |
Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis.
Topics: Acute Disease; Adult; Atorvastatin; Colitis, Ulcerative; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Placebo Effect; Prednisolone; Pyrroles; Severity of Illness Index | 2014 |
Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Coronary Artery Disease; Disease-Free Survival; Drug Administration Schedule; Emergencies; Female; Heart Failure; Hospitalization; Humans; Incidence; Inflammation Mediators; Interleukin-6; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prospective Studies; Risk Factors; Single-Blind Method; Surgical Procedures, Operative; Time Factors; Treatment Outcome | 2014 |
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Topics: Acute Disease; Adult; Aged; Allografts; Atorvastatin; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Survival Rate; Tissue Donors | 2016 |
Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Angiopoietin-Like Protein 2; Angiopoietin-like Proteins; Angiopoietins; Atorvastatin; Female; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Myocardial Infarction; Oxidative Stress; Prospective Studies; Treatment Outcome; Ventricular Function, Left | 2016 |
Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial.
Topics: Acute Disease; Aged; Atorvastatin; Biomarkers; Brain Ischemia; E-Selectin; Female; Humans; Inflammation; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interleukin-10; Interleukin-1beta; Interleukin-6; Intracranial Arteriosclerosis; Male; Middle Aged; P-Selectin; Stroke; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Functional dilator capacity is independently associated with insulin sensitivity and age in central obesity and is not improved by high dose statin treatment.
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Female; Heptanoic Acids; Humans; Hyperemia; Hyperinsulinism; Insulin Resistance; Male; Microcirculation; Middle Aged; Obesity, Abdominal; Pyrroles; Risk Factors; Vasodilation | 2011 |
Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Matrix Metalloproteinase 2; Prognosis; Pyrroles; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome | 2002 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors | 2003 |
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Topics: Acute Disease; Aged; Angina, Unstable; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pyrroles; Serum Amyloid A Protein; Syndrome; Troponin | 2003 |
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?
Topics: Acute Disease; Adult; Aged; Arginine; Atorvastatin; Biomarkers; Blood Glucose; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Statistics as Topic; Triglycerides | 2003 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2004 |
Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pyrroles | 2004 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Cilostazol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Tetrazoles; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2004 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Acute-Phase Proteins; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Female; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Secondary Prevention; Syndrome | 2005 |
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Topics: Acute Disease; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Pyrroles; Recurrence; Risk Factors; Treatment Outcome | 2005 |
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors | 2005 |
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome | 2005 |
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation | 2005 |
The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome.
Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Coronary Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Middle Aged; Peroxidase; Pyrroles; Syndrome | 2006 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Syndrome; Time Factors; Treatment Outcome | 2007 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis | 2007 |
Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
Topics: Acute Disease; Aged; Atorvastatin; Brain Ischemia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuroprotective Agents; Odds Ratio; Pyrroles; Risk Factors; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Withholding Treatment | 2007 |
Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
Topics: Acetylcholine; Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Chronic Disease; Endothelium, Vascular; Free Radical Scavengers; Heptanoic Acids; Humans; Hypertriglyceridemia; Injections, Intravenous; Male; Middle Aged; Nitroprusside; Pyrroles; Serotonin; Triglycerides; Vasodilation; Vasodilator Agents | 2000 |
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Platelet Aggregation; Pyrroles; Thromboplastin; Thrombosis | 2002 |
38 other study(ies) available for atorvastatin and Acute Disease
| Article | Year |
|---|---|
Atorvastatin-induced acute cholestatic hepatitis.
Topics: Acute Disease; Atorvastatin; Chemical and Drug Induced Liver Injury; Cholestasis; Hepatitis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2022 |
Atorvastatin improves the cardiac function of rats after acute myocardial infarction through ERK1/2 pathway.
Topics: Acute Disease; Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Echocardiography; Heart Function Tests; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Rats; Rats, Sprague-Dawley | 2019 |
Effects of atorvastatin combined with bivalirudin on coagulation function, cardiac function, and inflammatory factors of percutaneous coronary intervention in elderly patients with acute myocardial infarction.
Topics: Acute Disease; Aged; Atorvastatin; Blood Coagulation; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Acute bilateral cerebral infarction in the presence of neuromyelitis optica spectrum disorder: A case report.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Anticholesteremic Agents; Aphasia, Broca; Aspirin; Atorvastatin; Benzofurans; Cerebral Infarction; Female; Humans; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Neuromyelitis Optica; Neuroprotective Agents; Plasmapheresis; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction.
Topics: Acute Disease; Animals; Atorvastatin; Disease Models, Animal; Humans; Male; Mesenchymal Stem Cells; Myocardial Infarction; Rats; Time Factors | 2019 |
Atorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Pancreatitis; Risk Factors; Taiwan; Time Factors | 2016 |
Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats.
Topics: Acute Disease; Animals; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Diabetes Mellitus, Type 2; Drug Administration Schedule; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Wistar; Time Factors | 2009 |
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
Topics: Acute Disease; Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Atorvastatin; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Capillary Permeability; Down-Regulation; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Phospholipases A2, Cytosolic; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke; Time Factors | 2010 |
Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction.
Topics: Acute Disease; Albuminuria; Animals; Atorvastatin; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2010 |
Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Electrocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pyrroles; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2010 |
The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis.
Topics: Acute Disease; Animals; Atorvastatin; Colitis; Cytokines; Disease Models, Animal; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Mice; Mice, Inbred BALB C; Pyrroles; Th1 Cells; Th2 Cells | 2011 |
Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism.
Topics: Acute Disease; Animals; Atorvastatin; Bronchoalveolar Lavage; Drug Synergism; Enzyme Activation; Heart Ventricles; Hemodynamics; Heptanoic Acids; Lipid Peroxidation; Lung; Male; Matrix Metalloproteinases; Myocytes, Cardiac; Neutrophils; Oxidative Stress; Piperazines; Pulmonary Embolism; Purines; Pyrroles; Sildenafil Citrate; Sulfones | 2011 |
Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Drug Interactions; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Rhabdomyolysis; Warfarin | 2012 |
Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol.
Topics: Acute Disease; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Cell Survival; Chemotaxis, Leukocyte; Cholesterol; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Male; Molecular Structure; Monocytes; Neutrophil Infiltration; Neutrophils; Nitric Oxide Donors; Pyrroles; Rabbits | 2013 |
Rhabdomyolysis with concurrent atorvastatin and diltiazem.
Topics: Acute Disease; Acute Kidney Injury; Atorvastatin; Cardiovascular Agents; Chemical and Drug Induced Liver Injury; Diltiazem; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Rhabdomyolysis | 2002 |
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy.
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Drug Combinations; Heptanoic Acids; Humans; Male; Middle Aged; Pancreatitis; Pyrroles; Salicylates; Treatment Outcome | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Cost-Benefit Analysis; Economics, Pharmaceutical; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Secondary Prevention; Syndrome | 2003 |
Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; CD4 Lymphocyte Count; Coronary Disease; Epichlorohydrin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Immunophenotyping; Male; Prospective Studies; Pyrroles; Resins, Synthetic; Th1 Cells; Th2 Cells | 2004 |
[Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
Topics: Acute Disease; Adolescent; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analysis; Diagnosis-Related Groups; Double-Blind Method; Germany; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Patient Compliance; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Syndrome; Time Factors | 2004 |
Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?
Topics: Acute Disease; Aged; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatitis; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides | 2004 |
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Cost Savings; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Economics, Pharmaceutical; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Spain; Syndrome; Time Factors; Treatment Outcome | 2004 |
Statins in acute coronary syndromes: the sooner, the better?
Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Secondary Prevention; Syndrome | 2005 |
Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial".
Topics: Acute Disease; Antigen-Antibody Complex; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Phospholipids; Pyrroles; Reagent Kits, Diagnostic; Reproducibility of Results | 2005 |
Acute pancreatitis associated with combined lisinopril and atorvastatin therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; Humans; Lisinopril; Male; Pancreatitis; Pyrroles | 2005 |
The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD40 Ligand; Cholesterol; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Triglycerides | 2005 |
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome | 2005 |
[Acute cholestatic hepatitis after atorvastatin reintroduction].
Topics: Acute Disease; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Cholestasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2006 |
Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9.
Topics: Acute Disease; Analysis of Variance; Animals; Atorvastatin; Disease Models, Animal; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Injections, Intravenous; Luminescence; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microspheres; Nitrates; Nitrites; Proportional Hazards Models; Pulmonary Embolism; Pulmonary Wedge Pressure; Pyrroles; Random Allocation; Rats; Rats, Wistar; Survival Rate | 2007 |
The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Serum Amyloid A Protein; Statistics as Topic; Syndrome; Treatment Outcome; Triglycerides | 2006 |
Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
Topics: Acute Disease; Amides; Atorvastatin; Cardiac Pacing, Artificial; Clinical Trials as Topic; Fumarates; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pulmonary Edema; Pyrroles; Renin; Respiration, Artificial | 2007 |
Leukocyte, plasma, and organ-associated cytokine profiles in an animal model of acute inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cytokines; Disease Models, Animal; Down-Regulation; Endotoxemia; Female; Heart; Heptanoic Acids; Inflammation Mediators; Kidney; Leukocytes; Lipopolysaccharides; Myocardium; Organ Specificity; Pyrroles; Random Allocation; Swine; Up-Regulation | 2008 |
[Acute pancreatitis associated with atorvastatine therapy].
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Male; Middle Aged; Pancreatitis; Pyrroles | 2000 |
Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Atorvastatin; Drug Therapy, Combination; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Pyrroles; Rhabdomyolysis; Risk Factors; Surgical Wound Infection; Tibial Arteries | 2000 |
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |
Atorvastatin for acute coronary syndromes.
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2001 |
Atorvastatin for acute coronary syndromes.
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2001 |
Acute cholestatic hepatitis after reinitiating treatment with atorvastatin.
Topics: Acute Disease; Aged; Atorvastatin; Cholestasis; Hepatitis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2002 |